READ BEFORE ENTERING; This website is for information purposes only; This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of Top-life coach or its staff.
The Pneumonia Vaccination. A look deeper into the vaccine the way your doctor does not do.
We will also give you some information on the flu vaccination since you may also want some facts. The list of detrimental side effects of these two vaccinations is profound. You can see an abundance of evidence that the flu and pneumonia vaccines are very ineffective over the age of 65 yet still carry all the horrific potential side effects.
Keep in mind that when you read the words “rare side-effects,” their definition is 10% or less. A side effect of these vaccines varies from mild to death. Since they are not effective, you can decide for yourself if you want to take the risk.
Your pharmaceutically trained doctor who went to a pharmaceutically owned university makes a living prescribing pharmaceuticals so that they will have an extremely biased opinion. We encourage you to gather factual information from reliable sources and think for yourself. Below are some highlights of some science with links to the articles and studies for you to read.
There is an abundance of evidence of widespread manipulation of conclusions in studies. It would help if you also read who funded the studies and what the connection to pharma is.
Studies not funded or connected to pharma for-profit show significant differences in conclusions.
Pneumonia immunization in older adults: a review of vaccine effectiveness and strategies
From the ABSTRACT: The effectiveness of this strategy in preventing pneumonia has been in doubt despite the increase in vaccination coverage among older adults. The presence of selection bias and the use of nonspecific endpoints in these studies make the current evidence inconclusive in terms of overall benefit.
Simonsen et al. (3) analyzed influenza vaccine coverage and computed influenza-related mortality and all-cause deaths for 33 influenza seasons from 1968 to 2001 in the USA elderly population. The study found no correlation between increasing vaccination coverage after 1980 and declining mortality rates in any age group. Moreover, Simonsen and colleagues 3,79 argued that flu shots could not possibly have prevented more deaths than the 5%–10% of deaths that were flu-related. Assuming vaccine effectiveness of 50% against these winter deaths with no deaths attributable to influenza outside the winter months, the maximum percentage of all-cause winter mortality that could be prevented by the influenza vaccine would be about 2%–5%. Changes of such a small magnitude in all-cause deaths could easily be missed in ecological and observational studies.
From the CONCLUSION: Current US strategies to prevent pneumonia among older adults include recommending immunization with PPV and annual influenza vaccinations. However, the effectiveness of these vaccines decreases with increasing age and among individuals with comorbid conditions.
It should be noted that vaccination do NOT reduce pneumonia. A meta-analysis shows no decrease in pneumonia incidence as a result of vaccination.
We could not correlate increasing vaccination coverage after 1980 with declining mortality rates in any age group. Because fewer than 10% of all winter deaths were attributable to influenza in any season, we conclude that observational studies substantially overestimate vaccination benefit.
Pneumococcal vaccination in adults: Does it really work?
PPV does not appear to be particularly effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended. It is also uncertain whether PPV could affect the severity of the disease or the mortality rate.
Pneumococcal Vaccine: Vaccinate! Revaccinate?
Older and ill patients are those that revaccination is recommended, yet they respond least well to the vaccine (serologically). Age 65 is arbitrary. There are worse responses and a shorter length of efficacy with increasing age. We say to revaccinate high-risk patients; however, high-risk people respond least well to the vaccine and the shortest period of time.
There were no differences between vaccination rates among bacteremic patients (29 percent) and control patients (24 percent).
If the vaccine were protective, vaccination rates should be higher among the control patients, and serotype distribution should be different in vaccinated and nonvaccinated bacteremic patients. There were no differences between vaccination rates among bacteremic patients (29 percent) and control patients (24 percent). Furthermore, 65 percent of the blood isolates from nonvaccinated bacteremic patients were serotypes included in the vaccine compared with 69 percent of the isolates in vaccinated bacteremic patients. The pneumococcal vaccine did not appear to be protective in this high-risk population.
Efficacy of pneumococcal vaccine in high-risk patients
We were unable to demonstrate any pneumococcal vaccine’s efficacy in preventing pneumonia or bronchitis in this population. Our data suggest that chronically ill patients, who are most susceptible to infection, may have an impaired immune response to the pneumococcal vaccine.